Dr Pragya Yadav is Director-in-chargeof National Institute of One Health at Nagpur
   Date :24-Mar-2024

Dr Pragya Yadav 
 
 
 
 
Staff Reporter
 
 
Dr Pragya D Yadav, Scientist-F at the Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, has been appointed as the Director-in-Charge of the National Institute of One Health (NIOH), Nagpur. This post is in addition to her assignments at ICMR-NIV, Pune till further orders, cleared Jagdish Rajesh, Assistant Director General (Admin) in a letter. The letter issued by ICMR says, ‘ICMR is creating Biosafety infrastructure at different parts of the country, under the Pradhan Mantri-Ayushman Bharat Health Infrastructure Mission (PM-ABHIM) programme. It is felt that these infrastructure development works need specialised, dedicated and continuous scientific monitoring.’
 
Dr Yadav, is well-known for her research contributions in the field of communicable diseases and highly pathogenic viral infections such as Crimean Congo haemorrhage fever, Nipah, Ebola. In Nagpur at NIOH, Dr Yadav will also supervise the new BSL-4 (Biosafety level) and BSL-3 infrastructure facilities, under the PM-ABHIM, which is 4 new zonal NIVs. ‘The Hitavada’, on August 23, 2023, had published an interview of Dr Yadav where she had revealed the plan of establishing Centre for One Health in Nagpur on the lines of National Institute of Virology (NIV), Pune. Maharashtra Animal and Fisheries Science University (MAFSU) was to be the knowledge partner of the lab to be set up by the Indian Council for Medical Research (ICMR). The laboratory is being established on a four hectare land located opposite Nagpur Veterinary College at Seminary Hills.
 
Dr Yadav was among the team of scientists that detected the first three Covid-19 pandemic cases in the country. She played a key role in developing Covaxin. At NIOH, Biosafety levels 3, 4 are being set up with a ‘Multi-Institutional One Health’ approach, where several departments of Government of India will be working. ICMR-NIV contributed significantly during the coronavirus pandemic as it investigated potential antiviral drugs, undertook several kit validations, developed new diagnostics prepared Covaxin.